Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. (EPRX) generates a steady flow of news as a clinical-stage biotechnology company advancing drug candidates built on its Diffusphere™ drug delivery platform. Company updates focus on clinical data readouts, trial progress, financing events, and operational developments tied to its lead programs in eosinophilic esophagitis (EoE) and osteoarthritis.
A central theme in Eupraxia’s news is the RESOLVE trial for EP-104GI in EoE. Press releases detail Phase 1b/2a dose-escalation results, including tissue health outcomes measured by the EoE Histological Scoring System, symptom improvements via the Straumann Dysphagia Index, durability of response out to 52 weeks after a single administration, and safety and tolerability observations such as the absence of reported Serious Adverse Events and candidiasis in disclosed cohorts. Additional news covers the transition into and expansion of the randomized, placebo-controlled Phase 2b portion of RESOLVE and plans to increase patient numbers and dose levels.
Investors following EPRX news will also see pipeline and platform updates, including references to EP-104IAR for knee osteoarthritis and Eupraxia’s broader pipeline of long-acting formulations for inflammatory joint indications, oncology, and other potential disease areas. Financing announcements, such as public offerings of common shares under Canadian and U.S. prospectuses, provide context on how the company funds its clinical and preclinical programs, regulatory submissions, and manufacturing scale-up.
This news feed brings together clinical trial milestones, financial results, capital markets transactions, and conference participation disclosed by Eupraxia. Readers can use it to track how EP-104GI and EP-104IAR progress through development, how the Diffusphere™ platform is being applied across indications, and how management describes risk factors, cash runway, and strategic priorities over time.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) has completed a non-brokered private placement raising C$44.5 million through the issuance of 8,905,638 Series 1 Preferred shares at C$5.00 per share. The proceeds will fund clinical trials for EP104GI, research programs, and general corporate purposes. The company appointed Joseph Freedman, former Brookfield Asset Management executive, to its board. The Preferred Shares rank senior to common shares, are convertible to common shares on a one-to-one basis, and will earn dividends after three years. The company also terminated its C$12 million convertible debt facility.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced its participation at the American College of Gastroenterology Annual Scientific Meeting 2024 in Philadelphia, presenting two significant posters. The first poster (P2209), which received a Presidential Award, focuses on EP-104GI's pharmacokinetics and tolerability in mini-pigs. The second poster (P3911), designated as an 'Abstract of Interest,' presents efficacy and pharmacokinetic results from the RESOLVE Phase 1b/2a study's first four cohorts. Both presentations, scheduled for October 28-29, 2024, showcase the company's work on their extended-release fluticasone formulation for treating Eosinophilic Esophagitis.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) announced the publication of its Phase 2b SPRINGBOARD trial data for EP-104IAR in Lancet Rheumatology. The trial evaluated EP-104IAR for knee osteoarthritis treatment. Key findings include:
1. EP-104IAR demonstrated clinically significant and durable pain relief.
2. Minimal changes in glucose and cortisol were observed.
3. Stable fluticasone propionate concentrations in plasma were maintained.
The study involved 318 participants and met its primary endpoint, showing statistically significant improvement over placebo in WOMAC Pain at 12 weeks (p=0.004). Three of four secondary endpoints also showed significant improvement. The results suggest EP-104IAR's potential to become a best-in-class therapy for knee osteoarthritis, which affects over 30 million people in the U.S. alone.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company, has announced its participation in the United European Gastroenterology (UEG) Week 2024 in Vienna, Austria, from October 12-15, 2024. The company will present a poster featuring data from the RESOLVE trial, a Phase 1b/2a dose-escalation study of EP-104GI for Eosinophilic Esophagitis.
The presentation details include:
- Poster Number: PP0584
- Title: Results from Dose Escalation in RESOLVE, an Ongoing Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
- Topic: Oesophageal, gastric and duodenal
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) has announced key appointments to strengthen its senior management team. Dr. Amanda Malone, co-founder and former Chief Scientific Officer, has been promoted to Chief Operating and Scientific Officer. Dr. Rahul Sarugaser joins as Executive Vice President of Corporate Development.
Dr. Malone, who co-founded Eupraxia in 2012, has been instrumental in developing the company's DiffuSphere™ technology and leading successful clinical trials. Dr. Sarugaser brings 20 years of experience in capital markets and healthcare, most recently as Managing Director of Equity Research at Raymond James.
Eupraxia is advancing its DiffuSphere™ technology for targeted drug delivery in areas with high unmet medical need. The company's lead product, EP-104GI, is in a Phase 1b/2a trial for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial of EP-104IAR for knee osteoarthritis pain.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced its participation in the 20th International Symposium on Digestive Endoscopy (ISDE) World Congress for Esophageal Diseases in Edinburgh, Scotland, from September 22-24, 2024. The company will present a poster titled 'Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis'.
The presentation, scheduled for September 23, 2024, from 12:00 PM to 1:45 PM BST, will showcase data from cohorts one through four of the RESOLVE trial. It falls under the 'Benign Disease' theme and has been assigned paper number 265. Eupraxia, a clinical-stage biotechnology company, utilizes its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet needs.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating eosinophilic esophagitis (EoE). Key findings include:
- 10 of 11 evaluable patients in the first four cohorts experienced reduced symptom scores at 12 weeks
- The fourth cohort showed the greatest percentage change in histology scores to date
- No serious adverse events reported across all four fully-dosed cohorts
The fourth cohort data showed:
- 45% mean reduction in symptom scores at 12 weeks
- 39% mean reduction in histology composite stage scores
- 67% mean reduction in peak eosinophil counts
These results are comparable to currently approved EoE therapies. The company remains optimistic about further improvements as the trial progresses towards optimal dosing.
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. The company's presentation is scheduled for 8:00 a.m. ET on Monday, September 9, 2024. Interested parties can view the presentation via a provided link or on the company's website.
Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release products using its proprietary DiffuSphere™ technology. The company's lead product, EP-104GI, is currently in a Phase 1b/2a trial (RESOLVE) for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial (SPRINGBOARD) of EP-104IAR for osteoarthritis knee pain. The company is also developing a pipeline of long-acting formulations for inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) reported its Q2 2024 financial results. Key highlights include:
- Positive progress in the eosinophilic esophagitis (EoE) clinical program with EP-104GI
- Presentations on EP-104IAR for knee osteoarthritis (OA) at medical meetings
- Net loss of $6.1 million, down from $9.5 million in Q2 2023
- Cash position of $23.3 million as of June 30, 2024
- New C$12 million convertible debt facility announced post-quarter end
The company anticipates reporting new data from the RESOLVE study soon and plans to engage with the FDA in Q4 2024 regarding the EP-104GI program.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced a new C$12 million convertible debt facility with Yabema Capital and other current shareholders. The facility is available for drawdown within 120 days, subject to the release of the existing SVB Facility. The conversion price is set at C$4.84375 per Common Share.
The company has also provided an update on its existing SVB Facility, which matured on June 21, 2024, with a total liability of C$12 million. Eupraxia has fully discharged C$6 million to SVB Innovation Credit Fund and is in discussions for the remaining settlement. The company's cash reserves will be reduced by up to C$12 million to settle this debt.
Including the new convertible debt facility, Eupraxia anticipates having sufficient cash to fund operations until the second quarter of 2025.